Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.
3.
4.

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.

Xiao HQ, Tian RH, Zhang ZH, Du KQ, Ni YM.

Onco Targets Ther. 2016 Mar 14;9:1471-6. doi: 10.2147/OTT.S96160. eCollection 2016.

5.

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.

6.

Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Li M, Zhang Q, Fu P, Li P, Peng A, Zhang G, Song X, Tan M, Li X, Liu Y, Wu Y, Fan S, Wang C.

PLoS One. 2012;7(5):e37229. doi: 10.1371/journal.pone.0037229. Epub 2012 May 17.

7.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

8.

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.

Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA.

Lung Cancer. 2012 May;76(2):222-7. doi: 10.1016/j.lungcan.2011.10.021. Epub 2011 Nov 23.

PMID:
22115704
9.
10.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA.

Oncologist. 2009 Mar;14(3):253-63. doi: 10.1634/theoncologist.2008-0232. Epub 2009 Feb 16.

11.

Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP.

J Thorac Oncol. 2011 Jan;6(1):64-70. doi: 10.1097/JTO.0b013e3181f7c6d4.

12.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.

Clin Lung Cancer. 2010 Mar 1;11(2):126-31. doi: 10.3816/CLC.2010.n.017.

PMID:
20199979
14.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
15.

Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.

Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N.

Respirology. 2011 Nov;16(8):1210-20. doi: 10.1111/j.1440-1843.2011.02025.x. Review.

PMID:
21801275
16.

Chemotherapy for advanced non-small cell lung cancer in the elderly population.

Santos FN, de Castria TB, Cruz MR, Riera R.

Cochrane Database Syst Rev. 2015 Oct 20;(10):CD010463. doi: 10.1002/14651858.CD010463.pub2. Review.

PMID:
26482542
17.

Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.

Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M.

J Thorac Oncol. 2009 Dec;4(12):1530-6. doi: 10.1097/JTO.0b013e3181b9e608.

18.

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.

Li X, Wang H, Lin W, Xu Q.

Curr Med Res Opin. 2014 Nov;30(11):2295-304. doi: 10.1185/03007995.2014.909392. Epub 2014 Apr 30. Review.

PMID:
24701984
19.

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Nuijten MJ, Aultman R, Carpe├▒o Jde C, Vergnen├Ęgre A, Chouaid C, Walzer S, Siebert U.

Curr Med Res Opin. 2011 Nov;27(11):2193-201. doi: 10.1185/03007995.2011.626019. Epub 2011 Oct 4.

PMID:
21970659
20.

Supplemental Content

Support Center